Full Coverage

Kuvan Receives Positive Opinion From CHMP for European Approval

                   
prnewswire.com
Sep 25, 2008
        
Story Timeline:  103 days

Decision on Marketing Authorization Expected by End of 2008 NOVATO, Calif., Sept. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia (HPA) in patients with phenylketonuria (PKU)... [read full story]                    

Add Comment
Latest article on this story:

Merck Serono's Kuvan(R) Recommended for European Approval

 euroinvestor.co.uk Sep 26, 2008
First article on this story:

Kuvan Receives Positive Opinion From CHMP for European Approval

 earthtimes.org Sep 25, 2008
Selected publications with coverage of this story:
prnewswire.com earthtimes.org euroinvestor.co.uk finanznachrichten.de
RELATED
Found 2 documents:
                   

Merck Serono's Kuvan(R) Recommended for European Approval

finanznachrichten.de
Sep 26, 2008
        

GENEVA, Switzerland, September 26 /PRNewswire/ -- - Kuvan(R) had previously received Orphan Medicinal Product designation from the EMEA as the first orphan drug for the treatment of HPA. PKU and BH4 deficiency are rare...

                   

Kuvan Receives Positive Opinion From CHMP for European Approval

earthtimes.org
Sep 25, 2008
        

Decision on Marketing Authorization Expected by End of 2008 NOVATO, Calif., Sept. 25 NOVATO, Calif., Sept. 25 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that its partner Merck Serono, a division of...